Barry N. Paul, MD, FACRO

Parul N. Barry, MD, FACRO, discussed building programs early in a career and used low-dose radiotherapy and aromatase inhibitor tolerance to show how to demonstrate value.

Experts highlight advances in cellular therapies that were discussed at the 2026 National ICE-T Conference in Charlotte, North Carolina.

Using T-cell–redirecting therapies in less heavily pretreated populations may be a beneficial space to capitalize on, said Barry Paul, MD.

“Every patient [with multiple myeloma] should be offered CAR T before they’re offered a bispecific, with some rare exceptions,” said Barry Paul, MD.

Barry Paul, MD, listed cilta-cel, anito-cel, and arlo-cel as 3 of the CAR T-cell therapies with the most promising efficacy in patients with multiple myeloma.